S100A9 and Barrett esophagus: 20 also found highly increased expressions of miR‐196a in EAC and showed its anti‐apoptotic and growth‐promoting functions. The authors assessed the ability of miR‐196a to function as a biomarker of BE progression to low‐grade dysplasia, high‐grade dysplasia and EAC. Higher expressions of miR‐196a were observed in EAC and BE than in normal squamous mucosa 20. The authors furthermore confirmed that miR‐196a specifically targets S100A9 3’ UTRs, SPRR2C and KRT5 by miR‐196a‐mimic and luciferase reporter‐based assays 20.